1045 related articles for article (PubMed ID: 27438344)
1. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Park SK; Hong SH; Kim H; Kim S; Lee EK
Clin Ther; 2019 Jun; 41(6):1066-1079. PubMed ID: 31101372
[TBL] [Abstract][Full Text] [Related]
9. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal.
Borges M; Afonso-Silva M; Laires PA; Gouveia M; Alarcão J; Ascenção R; Costa J
Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):199-205. PubMed ID: 31219361
[No Abstract] [Full Text] [Related]
11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Chin KL; Zomer E; Wang BH; Liew D
Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
Gandjour A; Ostwald DA
Pharmacoeconomics; 2018 Oct; 36(10):1285-1296. PubMed ID: 30054868
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
McMurray JJV; Trueman D; Hancock E; Cowie MR; Briggs A; Taylor M; Mumby-Croft J; Woodcock F; Lacey M; Haroun R; Deschaseaux C
Heart; 2018 Jun; 104(12):1006-1013. PubMed ID: 29269379
[TBL] [Abstract][Full Text] [Related]
16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
17. An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.
van der Pol S; Degener F; Postma MJ; Vemer P
Value Health; 2017 Mar; 20(3):388-396. PubMed ID: 28292483
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
Zacà V
J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):597-605. PubMed ID: 30160656
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
Krittayaphong R; Permsuwan U
Clin Drug Investig; 2021 Oct; 41(10):907-915. PubMed ID: 34533783
[TBL] [Abstract][Full Text] [Related]
20. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
